Loading data for MNPR — first visit, this takes a few seconds.

알림

Monopar Therapeutics Inc. (MNPR)

NasdaqCM: MNPR · 실시간 가격 · USD

117.30

-6.54 (-5.28%)

종가 기준: Aug 20, 2026, 6:27 PM

-5.28% (1D)

데이터 없음

매수호가	108.7
시가총액	786.6M
매출 (ttm)	n/a
순이익 (ttm)	-17.84M
베타	1.51
EPS (ttm)	-2.2
P/E (ttm)	n/a
선행 P/E	-59.19
P/B (ttm)	6.01
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

매도호가	123
거래량	120,835
평균 거래량 (20일)	215,329
시가	122.01
전일 종가	123.84
일중 범위	116.91 - 122.08
52주 범위	29.18 - 124.82
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

MNPR 소개

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and M...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 19, 2019

직원 수 22

상장 거래소 NasdaqCM

티커 MNPR

웹사이트 https://www.monopartx.com

전체 기업 정보

재무 실적

2025년 Monopar Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -13.72M로, -11.99% 감소했습니다.

재무제표

어닝 서프라이즈

Monopar Therapeutics가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.62 예상치 상회 0.03, 및 -77.14% 전년 대비 감소.

다음 실적 발표

Monopar Therapeutics Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2개월 전 · Zacks

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

3개월 전 · Simply Wall St.

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

6개월 전 · Simply Wall St.

Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.

Key Insights Institutions' substantial holdings in Monopar Therapeutics implies that they have significant influence...

6개월 전 · Investor's Business Daily

Broadcom Stock Sees Improved Relative Strength Rating

In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Bro...

8개월 전 · Zacks

What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.

2 페이지 중 1

Monopar Therapeutics Inc. (MNPR)